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Background: This study was initiated to investigate the prognostic significance of circulating tumor cell (CTC)
enumeration and the predictive value of CTC HER2 expression for efficient anti-HER2 therapy in HER2-positive
metastatic breast cancer (MBC) patients.
Methods: Sixty HER2-positive MBC patients were enrolled in the present study. Before the initiation of systemic
treatment, CTCs from 7.5 ml of blood were analyzed using the CellSearch system. The progression-free survival (PFS)
of the patients was estimated using Kaplan-Meier survival curves.
Results: CTCs were detected in 45% (27/60) of the patients, who had shorter median PFS than those without CTCs
(2.5 vs. 7.5 months, P = 0.0125). Furthermore, referring to the standard HER2 testing that uses immunohistochemistry
(IHC), we proposed a CTC HER2-positive criterion, defined as >30% of CTCs over-expressing HER2. Among patients
undergoing anti-HER2 therapy, those with HER2-positive CTCs had longer PFS (8.8 vs. 2.5 months, P = 0.002). Among
patients with HER2-positive CTCs, the median PFS for those receiving anti-HER2 therapy was significantly longer
than those who were not (8.8 vs. 1.5 months, P = 0.001). Notably, up to 52% (14/27) of the HER2-positive patients
were CTC HER2-negative, and anti-HER2 therapy did not significantly improve the median PFS in these patients
(2.5 vs. 0.9 months, P = 0.499).
Conclusions: Our findings underscore the necessity of a comprehensive CTC analysis, which may provide valuable
prognostic and predictive information for optimizing individually tailored therapies in HER2-positive MBC patients.
To test this idea, additional large cohort, multi-center and prospective clinical trials are needed.Background
Human epidermal growth factor receptor 2 (HER2) is a
185 kDa transmembrane tyrosine kinase receptor encoded
by the HER2 gene on chromosome 17q21. HER2 over-
expression or amplification occurs in approximately 20%
of all breast cancer patients and is associated with aggres-
sive growth, short survival and poor prognosis [1-3].
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and lapatinib (Tykerb, GSK, Philadelphia, PA, USA) [4-7].
Therefore, HER2 is considered to be a vital prognostic and
predictive factor, and treatment of HER2-positive patients
remains one of the great therapeutic challenges in meta-
static breast cancer (MBC).
Despite therapeutic advances over the past decades, indi-
vidually tailored therapeutic regimens for HER2-positve
patients remain far from satisfactory. For example, the
benefit of single-agent anti-HER2 therapy, in the form of
either trastuzumab or lapatinib, is only in the range of
~25% [8]. There are three possible explanations for this
phenomenon. First, HER2-positive MBC patients may be
divided into subgroups with different prognoses. Second,
the initial assessment of HER2-positivity may be inaccurate
due to the inherent limitations of traditional methods,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation of results or technical limitations such as variability
in tissue processing and reagents [9]. Third, previous stud-
ies have demonstrated that there are inconsistencies in
HER2 expression between primary tumors and their me-
tastases [10,11]. Such inconsistencies indicate that tumor
cells are under constant evolvement or clonal selection and
that the detected HER2 status may not necessarily reflect
the patients’ real-time phenotypes. Therefore, it is critical
to discover more precise prognostic marker and real-time
methods for HER2 testing to optimize individualized thera-
peutic regimens for HER2-positive MBC patients.
Circulating tumor cells (CTCs) are cells that shed
from the tumor and enter the circulation, a process that
is required for cancer metastasis. Considerable efforts
have been made to develop technologies for CTC detec-
tion and characterization; among these technologies, the
CellSearch system (Veridex LLC, Raritan, NJ, USA) is
the only one approved by US Food and Drug Adminis-
tration (FDA) for clinical use in treating MBC [12,13].
CellSearch has a CTC detection cutoff of ≥5 cells/7.5 ml
blood, and it has been demonstrated to be an independ-
ent prognostic factor for the prediction of progression-
free survival (PFS) and the overall survival (OS) of MBC
patients [14-17]. In addition to detection, the molecular
characterization of CTCs is now recognized as a valuable
tool that can provide real-time information to distin-
guish subgroups of patients who can benefit from cer-
tain types of therapy [18,19]. Unfortunately, previous
studies failed to illustrate the prognostic value of CTCs
in HER2-positive MBC patients using CellSearch [20].
Although recent studies have made great efforts to com-
pare HER2 statuses between tumor tissue and CTCs
[18,19,21-29], a satisfactory CTC HER2-positive criter-
ion has not yet been established.
In the present study, we demonstrated that CTC enu-
meration using a modified cutoff has superior prognostic
value for HER2-positive MBC. Furthermore, we pro-
posed that HER2 positivity should be determined by
both the HER2 intensity of individual CTCs and the per-
centage of CTCs with that intensity. Using the criterion
defined as >30% of CTCs over-expressing HER2, we
found that HER2 expression in CTCs was different from
that in tumor tissues, and this expression could signifi-




Patients who showed clinical and radiological evidence
of metastatic breast cancer were randomly enrolled in
the present study. Eligible patients were required to
have measurable or evaluable disease, with an Eastern
Cooperative Oncology Group (ECOG) performancestatus score of 0 to 3 and a pathology report describing
their histological type and nodal status, as well as their
estrogen receptor (ER), progesterone receptor (PgR),
and HER2 statuses. A patient was considered HER2-
positive with an immunohistochemistry (IHC) score of
3+ or a fluorescent in situ hybridization (FISH) ratio of
more than 2.2. IHC scores of 0 and 1+ or a FISH ratio
of less than 1.8 were considered to be HER2-negative
[30].
Before the start of a new line or a new therapy cycle,
10 ml of blood was drawn. An interval of <7 days be-
tween the day of blood sampling and the initiation of
systemic treatment was required. All treatment decisions
for the patients were made according to the National
Comprehensive Cancer Network (NCCN) clinical prac-
tice guidelines (Breast Cancer V.2.2010) without know-
ing the patients’ CTC results. Disease status was
assessed and categorized according to Response Evalu-
ation Criteria in Solid Tumors (RECIST). After several
months of follow-up, the relationship between the quan-
tity and characteristics of CTCs and clinical outcome
was analyzed retrospectively.
All patients signed an informed consent to participate
in the study, which was approved by the ethics and sci-
entific committees of the Affiliated Hospital of the Acad-
emy of Military Medical Sciences.Isolation, enumeration and characterization of CTCs
CTC isolation, enumeration and characterization were
performed using the CellSearch system, according to
the manufacturer’s instructions as described elsewhere
[14-17]. Briefly, cells that expressed the epithelial cell ad-
hesion molecule (EpCAM) were immunomagnetically
enriched by the semiautomated sample preparation sys-
tem that was provided with the CellSearch epithelial cell
kit. The isolated cells were then automatically labeled
with fluorescently tagged monoclonal antibodies specific
for leukocytes (CD45-allophycocyanin) and epithelial
cells (cytokeratins (CK) 8-, 18- and 19-phycoerythrin)
and were stained with the nucleic acid dye 4′,6-
diamidino-2-phenylindole (DAPI). HER2 expression in
CTCs was assessed by staining the cells with a fluores-
cein isothiocyanate (FITC)-labeled anti-HER2 antibody
(Veridex LLC, Raritan, NJ, USA). The intensity of HER2
expression on CTCs was given a score of 0 (negative),
1+ (weak), 2+ (moderate or questionable), or 3+ (strong)
according to criteria described elsewhere [28,29].
According to tissue HER2 positive criterion using
immunohistochemistry (IHC) [30], which detects
HER2 protein expression with a similar technological
principle as immunofluorescent (IF), we set two
criteria for HER2 positivity in CTCs: either >30%
or >10% of CTCs over-expressing HER2. We then
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these two criteria.
Statistical analysis
Fisher’s exact test was used to test whether there was a
statistically significant difference between the number of
patients with a cut-off of 5 CTCs and those with 1 CTC as
baseline. PFS was defined as the time elapsed from the ini-
tial blood sampling to the documentation of disease pro-
gression (according to RECIST) or, if no progression was
observed during the follow-up, to the last follow-up visit.
Kaplan-Meier survival curves were generated based on the
CTC levels at baseline and the HER2 status of CTCs, and
the curves were compared using the log-rank test.
McNemar’s test was used to determine whether aTable 1 Pathological and clinical characteristics of HER2-posit
Characteristics Total No. patients (%)
CTC Count at baseline
≥1 <1
Overall 60 27 (45.0) 33 (55.0
Age (years)
Mean 48.8 46.6 50
Range 25-75 25-68 33-7
Histology
Ductal 49 24 (49.0) 25 (51.0
Lobular 3 0 (0.0) 3 (100.0
Others 8 3 (37.5) 5 (62.5
ER
Positive 24 9 (37.5) 15 (62.5
Negative 36 18 (50.0) 18 (50.0
PR
Positive 22 9 (40.9) 13 (59.1
Negative 38 18 (47.4) 20 (52.6
No. of Metastasis
1 19 5 (26.3) 14 (73.7
≥2 41 22 (53.7) 19 (46.3
Metastatic sites
Bone only 4 2 (50.0) 2 (50.0
Visceral only 7 2 (28.6) 5 (71.4
Bone and visceral 30 18 (60.0) 12 (40.0
DFS
≤12 months 11 3 (27.3) 8 (72.7
>12 months 39 19 (48.7) 20 (51.3
Therapy line
1 15 7 (46.7) 8 (53.3
2 9 2 (22.2) 7 (77.8
3 13 7 (53.8) 6 (46.2
≥ 4 23 11 (47.8) 12 (52.2statistically significant difference existed regarding varia-
tions in HER2 status between CTCs and histological
results. P values <0.05 were considered statistically signifi-
cant. Analyses were carried out using SAS software
version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics and CTC enumeration
From September 2010 to August 2011, 60 HER2-positive
MBC patients with a mean age of 49 years (range: 25 to 75
years) were enrolled in the present study. In addition, 11
HER2-negative MBC patients (10 of whom were ER-
positive) were enrolled as a control group. The patho-
logical and clinical characteristics of the patients are listed
in Table 1 and Additional file 1: Table S1, respectively. Asive patients at baseline
P No. patients (%) P
CTC Count at baseline
≥5 <5








10 (20.4) 39 (79.6)
0.481) 0 (0.0) 3 (100.0)
) 2 (25.0) 6 (75.0)
)
0.430
4 (16.7) 20 (83.3)
0.746
) 8 (22.2) 28 (77.8)
)
0.789
4 (18.2) 18 (81.8)
1.000
) 8 (21.1) 30 (78.9)
)
0.057
1 (5.3) 18 (94.7)
0.082
) 11 (26.8) 30 (73.2)
)
0.314
0 (0.0) 4 (100.0)
0.270) 1 (14.3) 6 (85.7)
) 8 (26.7) 22 (73.3)
)
0.306
3 (27.3) 8 (72.7)
0.671
) 7 (17.9) 32 (82.1)
)
0.470
3 (20.0) 12 (80.0)
0.329
) 1 (11.1) 8 (88.9)
) 1 (7.7) 12 (92.3)
) 7 (30.4) 16 (69.6)
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in 45% (27/60) of the HER2-positive patients, and the
CTC count ranged from 1 to 1140 with a mean value of
68. Of the HER2-positive patients with detectable CTCs,
56% (15/27) had a CTC count that ranged from 1 to 4. In
contrast, CTCs were detected in 80.0% (8/10) of the ER-
positive/HER2-negative patients, and only 25.0% (2/8) of
those patients had a CTC count that ranged from 1 to 4.
Two different cutoffs were used to divide patients into
two groups based on the CTC count at the initial blood
draw: the first cutoff was ≥1 CTC, and the other was ≥5
CTCs. There were no statistically significant differences
between the two groups in terms of age, histology, status
of hormone receptors (HRs) such as ER and PR, meta-
static sites and numbers, disease-free survival (DFS), and
therapy line.
Prognostic significance of CTC enumeration
At the 10-month follow-up visit, 57% (34/60) of the pa-
tients exhibited disease progression. Using a cut-off of ≥5
CTCs, no significant difference was found in the median
PFS between the two groups (3.3 vs. 5.1 months, P =
0.4563, Figure 1A), consistent with a previous report [20].
Considering the lower detection rate of CTCs in HER2-
positive patients described above and previously [19,20],
we used a lower cut-off and found that patients with ≥1
CTC had a significantly shorter median PFS than those
with <1 CTC (2.5 vs. 7.5 months, P = 0.0125, Figure 1B).
We also analyzed the median PFS for groups divided
based on cut-offs of ≥2, ≥3 and ≥4 CTCs, but we found no
significant differences (Additional file 3: Figure S1).
HER2 expression on CTCs
HER2 expression intensity in CTCs was given a score of
0, 1+, 2+, or 3+, according to the criteria described
previously [28,29], and representative images are shownFigure 1 Kaplan-Meier PFS plots of HER2-positive MBC patients with
time of the baseline blood draw. Coordinates of the dashed lines indicatein Figure 2. Additional file 2: Table S2 presents the
percentages of CTCs at given HER2 intensity scores in
both the HER2-positive and HER2–negative groups.
With the positive criterion defined as >30% of CTCs
over-expressing HER2 (3+), the positive and negative
coincidence rates of CTC HER2 were 48% (13/27) and
100% (9/9), respectively, compared with tumor tissue.
McNemar’s test demonstrated that the HER2 status of
CTCs was significantly different from that of tumor tis-
sues (Table 2, χ2 = 12.07, P = 0.0005).
HER2 Expression in CTCs as a tool for predicting anti-
HER2 therapy efficacy
Twenty-seven patients with a CTC count ≥1 were divided
into 4 groups based on their CTC HER2 status and
whether they were receiving anti-HER2 therapy. Groups 1
and 2 consisted of patients with HER2 3+ CTC >30%, and
groups 3 and 4 consisted of patients with HER2 3+ CTC
≤30%. Although all patients were histologically positive for
HER2 and therefore should have received anti-HER2 ther-
apy, patients in groups 2 and 4 did not receive the treat-
ment for economic reasons. Kaplan-Meier plots of the
PFS values for all of the groups are shown in Figure 3.
Statistical analysis demonstrated that among the patients
who received anti-HER2 therapy (N = 18, groups 1 and 3),
only those with HER2-positive CTCs have benefited (8.8
vs. 2.5 months, P = 0.002). Among the patients with
HER2-positive CTCs (N = 13, groups 1 and 2), the median
PFS for those receiving anti-HER2 therapy was signifi-
cantly longer than that for those without anti-HER2 ther-
apy (8.8 vs. 1.5 months, P = 0.001). Notably, up to 52%
(14/27) of the patients who were histologically assessed as
HER2-positive had HER2-negative CTCs (N = 14, groups
3 and 4), and anti-HER2 therapy did not significantly im-
prove the median PFS for these patients (2.5 vs. 0.9
months, P= 0.499). In addition, we also compared the PFS ofa cut-off of ≥ 5 (A) and ≥1 (B) CTCs. PFS was calculated from the
median survival time.
Figure 2 Representative images for the 0, 1+, 2+, and 3+ intensities of HER2 expression on CTCs.
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as well as HER2 (3+ and 2+) vs. HER2 (1+ and 0), but
found no significant difference (data not shown).Discussion
In this study, we found that CTC enumeration with a
cut-off of ≥1 but not ≥5 CTCs could serve as a useful
prognostic factor for HER2-positive MBC patients. CTC
enumeration using CellSearch (with a cut-off of ≥5
CTCs) is widely accepted as a prognostic factor for
MBC patients [14-17]; however, its prognostic power for




Tumor tissue HER2 Total
+ -
3+ >30% 13 0 13
3+ ≤30% 14 9 23
Total 27 9 36
χ2 = 12.07, P = 0.0005.cut-off for all subgroups of MBC patients. We found
that HER2-positive patients had relatively lower CTC
counts than ER-positive/HER2-negative patients. Our re-
sults were consistent with the report of Giordano et al.,
in which a larger proportion of HR-positive/HER2-nega-
tive patients had ≥5 CTCs than those with other tumor
subtypes (P = 0.024) [20]. In line with these findings,
Punnoose et al. found that the CTCs in a population of
HR-positive/HER2-negative patients displayed higher
levels of EpCAM, a CTC enrichment marker used in the
CellSearch system [19]. It is possible that the ≥5-CTCs
cut-off is an unsuitable prognostic indicator for a sub-
group of HER2-positive patients. We tried other possible
cut-offs and eventually found that the cut-off of ≥1 CTC
yielded significant differences in PFS. Our results indi-
cated that the underlying molecular subtype and gene
expression patterns might not be same for different sub-
type of patients and that an adapted cut-off should be
considered to make prognosis judgments for various
subgroups of patients.
Based on clinical outcomes, our results indicated that a
CTC HER2-positive criterion defined as >30% of CTCs
over-expressing HER2 could improve the response
Figure 3 Kaplan-Meier PFS plots of patients who have >30% or ≤30% of their CTCs with an HER2 intensity score of 3+, with or
without anti-HER2 therapy. PFS was calculated from the time of the baseline blood draw. Coordinates of the dashed lines indicate median
survival time.
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efforts have been undertaken to compare the HER2 status
of tumor tissue and CTCs and determine whether anti-
HER2 therapy would be beneficial. The studies summarized
in Additional file 4: Table S3 indicated that the HER2 status
of the CTCs was totally different from that of the tumor tis-
sue. The overall discrepancy rate between the two sample
sources ranged from 15% to 61%. More importantly, the
HER2 detection methods used in these studies varied, and
there is no current consensus on how HER2 positivity
should be determined in CTCs.
For the IF-based HER2 staining method used in the
CellSearch system, two HER2 positivity criteria were pro-
posed. According to Pestrin et al., CTCs can be defined as
HER2-positive if at least 50% of them were HER2-positive
by IF [27]. Riethdorf et al. [28] and Ignatiadis et al. [29]
noted that the intensity of HER2 staining using the
CellSearch system was variable, ranging from absent or
weak to intermediate and sometimes bright. They pro-
posed a model in which HER2 expression in CTCs was
scored as 0, 1+, 2+, or 3+ according to the staining inten-
sity of HER2 in 6 types of breast cancer cell lines with
known HER2 statuses [28,29]. CTCs were categorized as
HER2-positive if at least one CTC showed strong HER2
staining intensity; however, due to CTC heterogeneity, the
intensity of an individual CTC might not represent the
actual HER2 status of the patient.We postulated that a reasonable CTC HER2-positive cri-
terion should seek experience from IHC, which detect
HER2 protein expression with a similar technological
principle as IF. Most importantly, the criterion should be
validated by clinical evidence. The HER2 positive criterion
using IHC was defined as uniform and intense membrane
staining of >30% of invasive tumor cells membrane staining
(the original threshold was >10%) [30]. Accordingly, we
proposed and tested two criteria for HER2 positivity: >30%
or >10% of CTCs over-expressing HER2. Conceivably, such
criteria that combine qualitative and quantitative aspects
encompassed a comprehensive evaluation of the entire pool
of the isolated CTCs. Based on the patients’ clinical out-
comes, we found that only the 30% threshold could give
more precise instruction for anti-HER2 therapy.
Using this threshold, we found that, surprisingly, only
patients who have both HER2-positive tumor tissue and
CTCs could substantially benefit from anti-HER2 therapy.
Conversely, up to 52% (14/27) of the histologically HER2-
positive patients had actually HER2-negative CTCs, and
these patients may not benefit from anti-HER2 therapy.
Our results are consistent with the recent work of Niikura
et al., who reported that patients with HER2-positive pri-
mary breast tumors could not benefit from trastuzumab
therapy due to loss of HER2 in the metastases [11].
Our data underscore the importance and urgency of
HER2 testing in CTCs, which is a real-time and dynamic
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mors. Through CTC characterization, patients with HER2-
positive tumors and CTCs are strongly recommended to
undergo anti-HER2 therapy. Furthermore, patients who
have HER2-positive tumors but HER2-negative CTCs could
avoid overtreatment with anti-HER2 agents.
Even though our study may help select patients for anti-
HER2 therapy, it was an exploratory single-center study, and
the number of the enrolled patients was not adequate for
powerful statistical analysis. To obtainmore robust evidence,
large cohort, multi-center and prospective clinical trials
should be designed in the near future, in which therapeutic
decisions are based on HER2 analyses of both tumor tissue
and CTCs.Conclusions
Our data demonstrate that CTC enumeration with a modi-
fied cut-off is a valuable prognostic tool for HER2-positive
MBC patients. The HER2 status of CTCs may be different
from that of tumor tissues and can predict responses to
anti-HER2 therapy. Our findings underscore the necessity
of a comprehensive CTC analysis (regarding both number
and HER2 status), which may be a valuable prognostic and
predictive tool for optimizing individually tailored therapies
for HER2-positive MBC patients.Additional files
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